Cargando…

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates

Antibody-drug conjugates (ADCs) combining potent cytotoxicity of small-molecule drugs with the selectivity and excellent pharmacokinetic profile of monoclonal antibody (mAb) are promising therapeutic modalities for a diverse range of cancers. Owing to overexpression in a wide range of tumors, human...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xinling, Huang, Andrew C, Chen, Fahai, Chen, Hu, Li, Lele, Kong, Nana, Luo, Wenting, Fang, Jianmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826051/ https://www.ncbi.nlm.nih.gov/pubmed/35146330 http://dx.doi.org/10.1093/abt/tbac001

Ejemplares similares

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Benefits of Targeted Molecular Therapy to Immune Infiltration and Immune-Related Genes Predicting Signature in Breast Cancer
por: Chen, Fahai, et al.
Publicado: (2022)

Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
por: Zhang, Hang, et al.
Publicado: (2017)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
por: Guidi, Lorenzo, et al.
Publicado: (2023)

Development of potent antibody drug conjugates against ICAM1(+) cancer cells in preclinical models of cholangiocarcinoma
por: Zhu, Bing, et al.
Publicado: (2023)

Antibody-Drug Conjugates: Possibilities and Challenges
por: Nejadmoghaddam, Mohammad-Reza, et al.
Publicado: (2019)

Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer
por: Yu, Minghui, et al.
Publicado: (2023)

Targeting cancer with antibody-drug conjugates: Promises and challenges
por: Dean, Alexis Q., et al.
Publicado: (2021)

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
por: Najjar, Mariana K., et al.
Publicado: (2022)

An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index
por: Hui, Xiwu, et al.
Publicado: (2022)

Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells
por: Chiang, Zu-Chian, et al.
Publicado: (2020)

Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly
por: Farràs, Mercè, et al.
Publicado: (2019)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate
por: Satofuka, Hiroyuki, et al.
Publicado: (2023)

ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma
por: Zhang, Peng, et al.
Publicado: (2023)

JSKN003, A NOVEL BIPARATOPIC ANTI-HER2 ANTIBODY-DRUG CONJUGATE, EXHIBITS POTENT ANTITUMOR EFFICACY
por: Wang, Pilin, et al.
Publicado: (2023)

Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor
por: Zhuang, Weiliang, et al.
Publicado: (2023)

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
por: Albarrán, Víctor, et al.
Publicado: (2022)

Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models
por: Kuo, Wei-Ying, et al.
Publicado: (2018)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
por: Yonesaka, Kimio
Publicado: (2021)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody–Drug Conjugates
por: Feuillâtre, Ofelia, et al.
Publicado: (2020)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
por: Rainone, Michael, et al.
Publicado: (2023)

Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
por: Kamath, Amrita V., et al.
Publicado: (2015)

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
por: Xu, Yingying, et al.
Publicado: (2021)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours
por: Zhang, Jian, et al.
Publicado: (2023)

EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma
por: Capone, Emily, et al.
Publicado: (2017)

High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody libraries
por: Hou, Shin-Chen, et al.
Publicado: (2016)

A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer
por: Hong, Xuwei, et al.
Publicado: (2023)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices
por: Qin, Qiuping, et al.
Publicado: (2022)

Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody–drug conjugates
por: Kang, Min Sun, et al.
Publicado: (2021)

Enzyme-Based Labeling Strategies for Antibody–Drug Conjugates and Antibody Mimetics
por: Falck, Georg, et al.
Publicado: (2018)

Antibody–drug conjugates as novel anti-cancer chemotherapeutics
por: Peters, Christina, et al.
Publicado: (2015)

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia
por: Rainone, Michael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rru729k978dm7f0dc4as4q0s8a